Serotonin transporter (SERT) is a classic target of drug discovery for neuropsychiatric and digestive disorders, and against those disorders, plants of Nardostachys genus have been valued for centuries in the systems of Traditional Chinese Medicine, Ayurvedic and Unani. Herein, chemical investigation on the roots and rhizomes of Nardostachys chinensis Batal. led to the isolation of forty sesquiterpenoids including six new aristolane-type sesquiterpenoids and six new nardosinane-type sesquiterprenoids. Their structures were elucidated by extensive spectroscopic methods, combined with analyses of circular dichroism and single-crystal X-ray diffraction data. To explore natural product scaffolds with SERT regulating activity, a high-content assay for measurement of SERT function in vitro was conducted to evaluate the SERT regulating properties of these isolates. In conclusion, eleven compounds could be potential natural product scaffolds for developing drug candidates targeting SERT.
Serotonin transporter (SERT) is a classic target of drug discovery for neuropsychiatric and digestive disorders. At serotonin synapses in the central nervous system, SERT is responsible for the reuptake of 5-hydroxytryptamine into presynaptic neurons, and it is implicated in the occurrence of mood disorders, for instance, depression, anxiety or obsessive-compulsive disorder 1 . At enterochromaffin cells in the digestive system, SERT inactivates the stimulant effects of 5-hydroxytryptamine on gastrointestinal tract mucosa, and it plays important roles in the pathophysiology of digestive disorders such as irritable bowel syndrome, slow transit constipation and functional abdominal bloating 2, 3 . To screen SERT activity of the candidate compounds, the high-content assay for measurement of SERT function based on human embryonic kidney 293 cell line stably expressing human SERT (hSERT-HEK) and the fluorescent substrate 4-[4-(dimethylamino)phenyl]-1-methylpyridinium (APP + ) has been established 4, 5 , and this novel method is more feasible in practice than the traditional isotope labeling uptake assay.
To identify novel SERT regulators from natural products, Nardostachys chinensis Batal. (NCB) has been studied. NCB is mainly distributed in Sichuan, Gansu, Qinghai and Xizang areas in China. The root and rhizome of NCB have been used as both herbal drugs and functional foods for centuries to treat digestive disorders in traditional Chinese medicine 6 . Modern pharmacological studies demonstrated that NCB show bioactivities in against depression, arrhythmia, convulsion, myocardial ischemia and hypertension 7 . This plant was enriched with bioactive sesquiterpenoids, among which aristolane-, nardosinane-, and guaiane-types of sesquiterpenoids
Results and Discussion
Structure identification. The 70% aqueous ethanol extract of the air-dried roots and rhizomes of Nardostachys chinensis Batal. was subjected to various modern chromatographic isolation (including preparative thin layer chromatography, silica gel/Sephadex LH-20 column chromatography, and reversed-phase C 18 preparative/semipreparative high performance liquid chromatography) to give six new (compounds 3, 6, 7, 11, 14 and 18) and twelve known aristolane-type sesquiterpenoids (Fig. 1) , together with six new (compounds 19, 22-24, 26, and 30) and sixteen known nardosinane-type sesquiterpenoids (Fig. 2) . Based on the comparison of spectroscopic data with those previously reported, those known compounds were identified as nardoaristolone C (1) 10 , nardoaristolone B (2) 11 , 1(10)-aristolen-9β-ol (4) 12 , kanshone C (5) 13 , kanshone H (8) 14 , (−)-aristolone (9) 15 , (−)-(14β,15β)-aristolone (10) 16 , kanshone F (12) 8 , kanshone G (13) 8 , debilon (15) 17 , nardostachone (16) 18 , 1(10)-aristolen-2-one (17) 19 , nardosinone (20) 17 , nardosinonediol (21) 17 , kanshone A (25) 17 , kanshone E (27) 20 , isonardosinone (28) 20 , nardosinanone H (29) 9 , (4 S,4aR,5 R)-4a,5-dimethyl-4-(1-methylethenyl)-4a,5,6,7tetrahydronaphthalen-1(4 H)-one (31) 21 , nardosinanone I (32) 9 , nardosinanone B (33) 22 , nardosinanone G (34) 9 , nardosinanone M (35) 10 , nardonoxide (36) 12 , nardosinanone F (37) 9 , desoxo-nachinol A (38) 17 , narchinol B (39) 23 and narchinol A (40) 24 , respectively. The structures of the new compounds were deduced by analysis of extensive spectroscopic data [including HRESIMS, 1D/2D NMR, optical rotation and circular dichroism (CD) data].
Nardoaristolone C (1) was isolated as colorless needles. The 1 H and 13 C NMR data ( Supplementary Table S3 ) revealed that the structure of 1 was similar to that of nardoaristolone B (2), except that the two olefinic carbons (C-1 and C-9) in 2 were replaced by the two oxygenated carbons in 1 [δ C 60.1 (C-1) and δ C 69.4 (C-9), δ H 3.90 (1 H, s, H-1)], indicating the existence of an oxiran ring adjacent to carbonyl in 1. Analysis of the HSQC and HMBC spectroscopic data supported the assignments of its 1D NMR data, which were identical with those data recently reported by other groups in this April.
The relative configuration of compound 1 was revealed by single-crystal X-ray diffraction (Mo Kα) data, together with the NOESY correlations between δ H 1.97 (H-6) and δ H 1.04 (H 3 -13) , and between δ H 1.56 (H 3 -12) and δ H 2.57 (H-4)/1.20 (H 3 -11) . For X-ray crystallographic analysis of light atom structures (those containing only C, H, N or O), if a heavier element (such as chlorine, bromine or sulfur) is not contained in the crystals, the anomalous scattering with molybdenum (Mo) radiation is always too small to assign the absolute configuration 25 . Herein, the absolute configuration of 1 was then assigned by comparing its CD data with those of 2 ( Supplementary Fig. S79 ), both sharing a positive Cotton effect at 215 ± 5 nm and a negative Cotton effect at 255 ± 2 nm, which were identical with the reported data 10 . Nardoaristol (3) was isolated as a colorless oil, and epoxynardosinone (19) was isolated as colorless crystals. Their molecular formulas were confirmed respectively to be C 15 Table S3 and Table 1 ) demonstrated that the structures of 3 and 19 were similar to those of 1(10)-aristolen-9β-ol (4) and nardosinone (20) , except that the olefinic carbons (C-1 and C-10) in 4 and 20 were replaced by the oxygenated carbons of two oxiran rings in 3 [δ C 57.4 (C-1) and δ C 66.7 (C-9), δ H 3.47 (1 H, d, J = 2.4 Hz, H-1)] and 19 [δ C 60.2 (C-1) and δ C 61.9 (C-10), δ H 3.92 (1 H, br s, H-1)], respectively. The deduction was further confirmed by analysis of the HSQC and HMBC spectroscopic data and the relative configurations of 3 and 19 were assigned by the 2D NOESY experiments ( Fig. 3) . Similarly, the structure of epoxynardosinanone H (30) was established by comparison of its 1D/2D NMR spectroscopic data with those of nardosinanone H (29).
3-Hydroxylkanshone H (6) was isolated as a colorless oil, and 3-oxokanshone H (7) was isolated as a white amorphous powder. Analysis of their ESIMS and NMR data established the molecular formulas to be C 15 Based on the above deduced relative configurations, the absolute configurations of the new compounds 6, 7, 19 and 30 were proposed by comparing their experimental CD data with those of the known aristolane-type and nardosinane-type sesquiterpenoids isolated from NCB ( Supplementary Fig. S79 ), which normally share the same intrinsic absolute configurations for stereogenic carbons C-4, 5, 6 and 7, owing to the relatively conservative biogenic pathway of sesquiterpenoids in NCB. The structures of compounds 6-8 possess similar chromophores 26 , and then they showed similar patterns of CD curves as shown in Supplementary Fig. S79 . When compared with 8, 3-hydroxyl substitution seemed to weaken the positive cotton effect around 245 nm in 6, while 3-ketone substitution was prone to reverse the shoulder peak around 300 nm to be a "valley"-style curve in 7. Assignments of the absolute configurations of 3 was fairly challenging owing to its structure without any cyclic ketone group. Considering that 3 was a 1(10)-epoxidation derivative of the known aristolane-type sesquiterpenoid (4) and its CD spectrum also showed negative Cotton effects (<215 nm), the absolute configuration of 3 was proposed as shown in Fig. 1 .
Based on the comparisons of 1D/2D NMR data, 1-hydroxylaristolone (11) and 9β-debilon (14) were found out to be two new stereoisomers of the reported structures axinysone B 27 and debilon (15) , respectively. 1D NMR data of 11 was exactly the same as those reported for axinysone B, but the optical rotation and CD data of 11 was opposite to those of axinysone B, indicating that the two compounds are a pair of enantiomers. The experimental CD spectrum of 11 was further compared with the computational ECD spectra of the (1 S,4 R,5 R,6 S,7 R)-11a and (1 R,4 S,5 S,6 R,7 S)-11b obtained by time-dependent density functional theory (TDDFT) quantum mechanics [B3LYP/6-31 G(d)] 28 . The excellent agreement of the experimental and computational ECD spectra (see Supplementary Fig. S80 ) confirmed the assignment of the absolute configuration of 11 as (1 S,4 R,5 R,6 S,7 R). 14 was elucidated as a 9β-hydroxyl epimer of 15 (debilon) by analysis and comparison of the spectroscopic data (including 1D/2D NMR, ORD and CD data) for compounds 14 and 15.
Aristolanhydride ( The structures of other four new nardosinane-type sesquiterpenoids, nardosinonetriol (22), 7-oxonardosinone (23), 7-oxonardosinoperoxide (24) and 2-oxokanshone A (26), were established by comparing their NMR data ( Supplementary Tables S3-S4 and Table 1 ) with those of known compounds 21 (nardosinonediol) and 25 (kanshone A). Compound 24 was deduced as a peroxide compound on the basis of its positive HRESIMS (m/z 267.1589 [M + H] + , cald for C 15 H 23 O 4 + , 267.1591) and NMR data. Furthermore, the absolute configurations of these compounds were all proposed as shown in Fig. 2 based on the consideration of conservative biogenic pathway for nardosinane-type sesquiterpenoids, assisted by 2D NOESY experiments as shown in Fig. 3 . The plausible biosynthetic pathways for aristolane-and nardosinane-types of sesquiterpenoids were proposed as shown in Supplementary Figures S82-S83 . (36) and desoxo-nachinol A (38) showed potent effects, among which a 4,11-O-briged nardosinane-type sesquiterpenoid (nardonoxide, 36) with a 5/6/6 tricyclic ring system showed the strongest effect; 1(10)-aristolen-9β-ol (4), kanshone H (8), nardostachone (16), 7-oxonardosinoperoxide (24) , kanshone E (27) and nardosinanone H (29) were in the middle; and 3-hydroxylkanshone H (6), 3-oxokanshone H (7), 1-hydroxylaristolone (11), epoxynardosinone (19), 7-oxonardosinone (23), isonardosinone (28) , nardosinanone I (32) and nardosinanone B (33) showed weak effects, however, 8 exhibited stronger effect than its 3-hydroxyl derivative (6) and 3-oxo derivative (7) , 23 exhibited weaker effect than its 9-peroxide derivative (24), and 28 showed weaker effect than its 2-oxo derivative (27) . For the SERT inhibitors, kanshone C (5), nardosinone (20) and nardosinonediol (21) significantly inhibited SERT activity. Further analysis suggested that 1(10) or 1(9)-epoxidation of the double bond (as shown in cases of 1/2, 19/20 and 30/31) seems to inactivate or reverse the aristolane-type and nardosinane-type sesquiterpenoids' regulation effects on SERT activity.
SERT regulating activities. As shown in
Both enhancer and inhibitor of SERT, interestingly, were identified in the two main types of sesquiterpenoids (subdivided into five subtypes I, II, III, IV and V) from NCB, and the SERT enhancers are richer in quantity than the SERT inhibitors. According to the proposed biosynthetic pathways (see Supplementary Figures S82-S83 ), it suggests that there exist conversions between SERT enhancers and SERT inhibitors in NCB. For instance, the SERT inhibitor kanshone C (5), and the SERT enhancers 1(10)-aristolen-9β-ol (4) and nardostachone (16) , are derived from compound 4.
Reported or marketed clinical antidepressants of the SERT mechanism, as known, include SERT inhibitors as well as SERT enhancers. SERT inhibitors (SIs) are dominant containing tricyclic antidepressants, selective serotonin reuptake inhibitors and selective noradrenaline reuptake inhibitors 29 , while the selective enhancer of SERT is rare and the only one in clinical use is tianeptine 30 . So far, hundreds of known SIs 31-52 , including 3-(aminoalkyl)-5-fluoroindole 53 , have been developed by chemical modification or hybridization of the known clinical antidepressants, based on the molecular templates shown in Fig. 4 . Although the molecular structures of known SIs are diverse, they usually contain heterochains and/or heterocycles of N, O, and/or S, with halogen-substituted phenyls (F or Cl) as the common substituents. In spite of this, few SIs of natural products have been discovered, the only example, cyclo(L-Phe-L-Phe) found in chicken essence, is a dual inhibitor of SERT and acetylcholinesterase 54 . As far as we know, this is the first report on SERT activities of the natural aristolane-type and nardosinane-type sesquiterpenoids. Further, according to the above structure-activity discussion of known SIs, it suggests that eleven compounds ( Fig. 5 ) including eight SERT enhancers (nardonoxide, nardoaristolone B, desoxo-nachinol A, 1(10)-aristolen-9β-ol, kanshone E, nardosinanone H, kanshone H, nardostachone, S1-S8) and three SERT inhibitors (kanshone C, nardosinonediol, nardosinone, S9-S11) may provide novel potential scaffolds for synthesis of SERT regulators.
In conclusion, forty sesquiterpenoids were isolated from roots and rhizomes of Nardostachys chinensis Batal., and their structures were identified by combined modern spectroscopic methods. Among these compounds, eleven natural scaffolds bidirectionally regulate SERT activity. They are potential lead compounds for regulation of SERT activity in drug discovery and provide novel molecular templates for synthesis of SERT enhancers and inhibitors, especially enhancer of SERT, which is rare so far in drug discovery. Presently, we are exploiting more SERT regulation lead structures from NCB and investigating antidepressant effect of SERT regulators in vivo assays to be reported in due time.
Methods
General experimental procedures. Optical rotations were measured using a Rudolph AUTOPOL V polarimeter (Rudolph Research Analytical, Hackettstown, USA). UV and electronic circular dichroism spectra were obtained on a Jasco J-815 circular dichroism spectropolarimeter (JASCO Corporation, Tokyo, Japan). ESIMS was performed on a Waters Synapt G2 mass spectrometer (Waters, Milford, MA, USA), and HRESIMS spectra was obtained on a quadrupole time-of-flight mass spectrometer QSTAR TM Elite system (Applied Biosystems/ MDS Sciex, Foster, CA, USA; Concord, ON, Canada). 1D and 2D NMR spectra were recorded on a Bruker AV-III spectrometer ( 1 H/ 13 
24:
IV 11-hydroxy-9-hydroxyperoxy-1(10),8(9)-dien-7-one 1.06 ± 0.02 1.11 ± 0.02*** 1.12 ± 0.02*** ↑↑ 28: 11-hydroxy-7β,8β-epoxy-1(10)-en-9-one 1.08 ± 0.02** 1.10 ± 0.01*** 1.09 ± 0.02*** ↑ 19: 1α,10α-epoxy-7β,11-peroxy-9-one 1.01 ± 0.01 0.99 ± 0.02 1.09 ± 0.02*** ↑ 32: 11α,12α-epoxy-1(10),7(8)-dien-9-one 1.05 ± 0.01* 1.08 ± 0.02*** 1.07 ± 0.02*** ↑ 33: 7β-hydroxy-10β,11β-epoxy-2,9-dione 1.07 ± 0.01** 1.05 ± 0.01 1.08 ± 0.02** ↑ Supplementary Table S1 and Table 1 ;
3-Hydroxylkanshone H (6) . Colorless oil (EtOAc); [α]20 D = −50.13 (c 0.5, MeOH); UV (MeOH) λ max 283.0; CD (c 0.05, MeOH) λ(Δε) 213.5 (+1.32), 275.5 (+0.08), 296.0 (+0.66), 336.5 (−3.55); 1 H NMR (CDCl 3 , 400.13 MHz) and 13 C NMR data (CDCl 3 , 100.61 MHz), see Supplementary Table S1 and Table 1 Epoxynardosinone (19) . Colorless crystals (EtOAc); [α]20 D = +1.27 (c 1.0, MeOH); UV (MeOH) λ max 197.0; 1 H NMR (CDCl 3 , 400.13 MHz) and 13 C NMR data (CDCl 3 , 100.61 MHz), see Supplementary Table S3 and Table 1 Supplementary Table S3 and Table 1 Supplementary Table S3 and Table 1 X-ray crystallographic analysis of 1. The structure were solved by SHELXS-97 and refined by full-matrix least-squares techniques using the SHELXL-97 program. Crystallographic data for the structure of 1 reported in this study has been deposited with the Cambridge Crystallographic Data Centre under the reference number CCDC 1058758. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).
Crystal data for 1. Colorless prism, C 14 D calcd = 1.257 g/cm 3 , F 000 = 252. Mo Kα radiation, λ = 0.71073 Å, T = 113(2) K, μ (Mo Kα) = 0.087 mm −1 . The final R 1 was 0.0443 and wR 2 was 0.0852. Computational methods. Relative configurations of 11 and 18 were deduced by analysis of their 1D/2D NMR data. Stochastic conformational searches were firstly conducted under MMFF94 force field to give one and three possible conformers for 11 and 18, respectively. Conformers were then optimized and the frequencies were calculated by further time-dependent density functional theory (TDDFT) method to verify their stability. Using the conformers at the B3LYP/6-31 G(d) basis set level in methanol, sixty excitation states at the B3LYP/6-31 G(d) basis set level were calculated, and finally the calculation results were Boltzmann averaged to yield the depicted electronic circular dichroism (ECD) spectra of 11 and 18 with half bandwidths of 0.45 eV and 0.40 eV, respectively. All calculations were performed by Gaussian 09 program package (Version C.01).
SERT activity assay. The SERT activity assay was based on the reported method 4,5 with modifications. To evaluate SERT activity of these compounds, a validated stably transfected hSERT-HEK293 cell line were used in the high content assay. The fluorescent substrate 4-[4-(Dimethylamino)phenyl]-1-methyl pyridinium (APP + ) was used to examine SERT activity and the fluorescent dye Hoechst 33342 stain cellular nuclei. The effects of test compounds on SERT function were calculated by the following equation: Relative fluorescent intensity (RFI) = (Intracellular APP + fluorescent intensity treatment /Intracellular APP + fluorescent intensity control ). The positive control drugs in testing SERT function include SSRI fluoxetine 2.0 μM and SSRE tianeptine 1.0 μM. All test compounds were run in triplicates with three repeat times. The data from the SERT function assays were analyzed by using SPSS software (Version 11.5, IBM Company). The RFI values under different treatments were evaluated by one-way analysis of variance (ANOVA), followed by post hoc testing using Dunnett's multiple comparisons tests. The results were expressed in Mean ± S.E.M. 55 . Some available compounds were re-purified to make sure their purities ≥95% (HPLC, wavelengths = 230, 254, 280, 360 nm) before bioactivity evaluation.
